Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1

Status

Completed 3

Sponsor Class

OTHER 12INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 2Tumor-Agnostic 1

Conditions

Zollinger-Ellison Syndrome 1Stomach Ulcer 1Neoplasms 1Neoplasm Metastasis 1Esophagitis, Peptic 1Barrett Esophagus 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lansoprazole × Clear all
NCT02625259 2018-01-08

A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants

Takeda

Phase 1 Completed
54 enrolled 16 charts
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00942175 2012-02-03

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Takeda

Phase 1 Completed
160 enrolled 16 charts
Gastrointestinal

Esophagitis, Peptic, Stomach Ulcer, Zollinger-Ellison Syndrome

NCT00352261 2009-03-26

An Open Label pH Comparison of Esomeprazole and Lansoprazole in Barrett's Esophagus Patients

AstraZeneca

Phase 4 Completed
80 enrolled
Gastrointestinal

Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡